- Home
- WLFC vs ETNB Comparison
WLFC vs ETNB Comparison
Compare WLFC & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLFC
- ETNB
- Stock Information
- Founded
- WLFC 1985
- ETNB 2018
- Country
- WLFC United States
- ETNB United States
- Employees
- WLFC N/A
- ETNB N/A
- Industry
- WLFC Industrial Specialties
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- WLFC Consumer Discretionary
- ETNB Health Care
- Exchange
- WLFC Nasdaq
- ETNB Nasdaq
- Market Cap
- WLFC 1.2B
- ETNB 1.5B
- IPO Year
- WLFC 1996
- ETNB 2019
- Fundamental
- Price
- WLFC $149.03
- ETNB $8.87
- Analyst Decision
- WLFC
- ETNB Strong Buy
- Analyst Count
- WLFC 0
- ETNB 10
- Target Price
- WLFC N/A
- ETNB $27.22
- AVG Volume (30 Days)
- WLFC 57.1K
- ETNB 1.5M
- Earning Date
- WLFC 11-03-2025
- ETNB 11-06-2025
- Dividend Yield
- WLFC 0.67%
- ETNB N/A
- EPS Growth
- WLFC 30.03
- ETNB N/A
- EPS
- WLFC 16.84
- ETNB N/A
- Revenue
- WLFC $637,163,000.00
- ETNB N/A
- Revenue This Year
- WLFC $16.17
- ETNB N/A
- Revenue Next Year
- WLFC $4.88
- ETNB N/A
- P/E Ratio
- WLFC $8.85
- ETNB N/A
- Revenue Growth
- WLFC 32.40
- ETNB N/A
- 52 Week Low
- WLFC $97.54
- ETNB $4.16
- 52 Week High
- WLFC $235.43
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- WLFC 50.48
- ETNB 43.45
- Support Level
- WLFC $143.39
- ETNB $8.46
- Resistance Level
- WLFC $157.55
- ETNB $9.47
- Average True Range (ATR)
- WLFC 4.92
- ETNB 0.46
- MACD
- WLFC -0.98
- ETNB -0.02
- Stochastic Oscillator
- WLFC 39.55
- ETNB 33.33
About WLFC Willis Lease Finance Corporation
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).